{"id":7861,"date":"2024-10-19T13:29:56","date_gmt":"2024-10-19T05:29:56","guid":{"rendered":"https:\/\/flcube.com\/?p=7861"},"modified":"2024-10-19T13:30:00","modified_gmt":"2024-10-19T05:30:00","slug":"akeso-biopharma-launches-phase-ib-ii-trial-for-cadonilimab-and-ak112-in-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7861","title":{"rendered":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer"},"content":{"rendered":"\n

On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926<\/a>) has initiated a Phase Ib\/II clinical study to evaluate the combination of Cadonilimab (CTLA-4\/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1\/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.<\/p>\n\n\n\n

The primary endpoints of the study include safety, assessed by the incidence of adverse events and serious adverse events, as well as overall response rate (ORR). Secondary outcomes will evaluate pharmacokinetics, anti-drug antibodies, progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and time to response (TTR).<\/p>\n\n\n\n

Currently, neither Envafolimab nor Cadonilimab has been approved for the treatment of pancreatic cancer. According to the PharmaCube database, Akeso Biopharma has previously launched a Phase II clinical study (NCT06491472) investigating Envafolimab in combination with chemoradiotherapy for pancreatic cancer, along with several Phase II studies of Cadonilimab as monotherapy and in combination with other agents for the same indication (NCT06532617, NCT06153368, CTR20230810).- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib\/II…<\/p>\n","protected":false},"author":1,"featured_media":7863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[360,16,62,850],"class_list":["post-7861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-9926"],"yoast_head":"\nAkeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib\/II clinical study to evaluate the combination of Cadonilimab (CTLA-4\/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1\/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7861\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7861\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-19T05:29:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-19T05:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma Launches Phase Ib\\\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer\",\"datePublished\":\"2024-10-19T05:29:56+00:00\",\"dateModified\":\"2024-10-19T05:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg\",\"keywords\":[\"Akeso Biopharma\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9926\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7861#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7861\",\"name\":\"Akeso Biopharma Launches Phase Ib\\\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg\",\"datePublished\":\"2024-10-19T05:29:56+00:00\",\"dateModified\":\"2024-10-19T05:30:00+00:00\",\"description\":\"ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib\\\/II clinical study to evaluate the combination of Cadonilimab (CTLA-4\\\/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1\\\/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7861\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg\",\"width\":900,\"height\":600,\"caption\":\"Akeso Biopharma Launches Phase Ib\\\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7861#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma Launches Phase Ib\\\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry","description":"ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib\/II clinical study to evaluate the combination of Cadonilimab (CTLA-4\/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1\/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7861","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7861","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-19T05:29:56+00:00","article_modified_time":"2024-10-19T05:30:00+00:00","og_image":[{"width":900,"height":600,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7861#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7861"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer","datePublished":"2024-10-19T05:29:56+00:00","dateModified":"2024-10-19T05:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7861"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=7861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","keywords":["Akeso Biopharma","Cancer","Clinical trial approval \/ initiation","HKG: 9926"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7861#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7861","url":"https:\/\/flcube.com\/?p=7861","name":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=7861#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=7861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","datePublished":"2024-10-19T05:29:56+00:00","dateModified":"2024-10-19T05:30:00+00:00","description":"ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib\/II clinical study to evaluate the combination of Cadonilimab (CTLA-4\/PD-1 dual antibody) and AK112 (Envafolimab, a PD-1\/VEGF dual antibody) with chemotherapy as a first-line treatment for pancreatic cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7861#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7861"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=7861#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","width":900,"height":600,"caption":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7861#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma Launches Phase Ib\/II Trial for Cadonilimab and AK112 in Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0874fab6-aa87-44af-bf42-3a5325399d79.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7861"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7861\/revisions"}],"predecessor-version":[{"id":7864,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7861\/revisions\/7864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/7863"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}